Kalina Pavlova Stoyanova

Dr. Kalina Pavlova Stoyanova


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2018 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
TCTatyana Cvetkova
Tatyana Cvetkova
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
TPTsonko Paunov
Tsonko Paunov

1 June 2019 in Helminthologia
Verified
Journal Article
Open access
PDF file
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
SPStoyan Pavlov Pavlov
Stoyan Pavlov Pavlov
TCT. Cvetkova
T. Cvetkova
TPTsonko Paunov
Tsonko Paunov
Sciendo provides publishing services and solutions to academic and professional organizations and individual authors. We publish journals, books, conference proceedings and a variety of other publications.

1 July 2021 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Closed access
TCTatyana Cvetkova
Tatyana Cvetkova
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
TPTsonko Paunov
Tsonko Paunov
SPStoyan Pavlov Pavlov
Stoyan Pavlov Pavlov

6 October 2017 in Journal of IMAB – Annual Proceeding (Scientific Papers)
Verified
Journal Article
Open access
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
TCTatyana Cvetkova
Tatyana Cvetkova
Stela DragomanovaStela Dragomanova
Stela Dragomanova
SPStoyan Pavlov Pavlov
Stoyan Pavlov Pavlov
The effective etiological antiparasitic treatment fulfils two major goals - to cure the infected patient and to terminate its role as an epidemiologically relevant source of infection. \ud The purpose of this study is to evaluate the effectiveness of the pharmacotherapy against the most common intestinal helminthic and protozoal infections diagnosed in Varna region.\ud Material and Methods: 879 patients with laboratory-confirmed intestinal parasitoses were treated etiologically with the established anthelminthic and antiprotozoal agents. Mandatory and active post-treatment laboratory monitoring served as the basis for the assessment of the therapy effectiveness.\ud Results: Enterobiasis has the highest prevalence of the intestinal parasitic infections with estimated treatment success of 94,7% at the end of the mandatory period and nearly 100% at the end of our monitoring. The significantly greater rate of relapses was registered among the patients with the two most common protozoal invasions – Giardiasis (9,5%) and Blastocystosis (6,7 %). Our analysis established that the main factors limiting the effective antiparasitic pharmacotherapy are extraneous, i.e. independent of the pharmacological properties of the agent or parasite’s biology. The most prominent reasons for therapy failure are poor or missing compliance to the therapy regimen, inadequate form or dosage of the medication, unrecognized source of (re)invasion, etc.\ud In conclusion, the collaboration between the general practitioners, clinical parasitologists and respectively the patients themselves is crucial for achieving an effective therapy and the resultant control of the intestinal parasitoses

1 April 2016 in Scripta Scientifica Medica
Verified
Journal Article
Open access
PDF file
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
TCTatyana Cvetkova
Tatyana Cvetkova
SPStoyan Pavlov Pavlov
Stoyan Pavlov Pavlov
STSvetoslav Todorov
Svetoslav Todorov
MGMargarita Gospodinova
Margarita Gospodinova
Introduction and aim: The objective of this study is to determine the structure of the outpatient parasitology tests and the epidemiological significance of the resultant morbidity for intestinal and non-intestinal parasitic diseases in Varna region, Northeastern Bulgaria. Materials and methods: A total number of 30 687 patients tested for human parasites were investigated. Statistical analyses were performed regarding the proportion of the tests by indications and the consequential prevalence of parasitic diseases was estimated. Results: The main percentage of outpatient tests is performed with prophylactic purposes (91.38%), followed by clinical (7.67%) and epidemiological (0.95%) indications. Significant concern represents the discovered prevalence of parasitic diseases with person-to-person and food-borne routes of transmission in children (Enterobiosis – 1.18%, Giardiasis – 0.78%) and in the active adult population (Giardiasis – 0.75%, Enterobiosis – 0.59%). The higher extensity of the diseases with other mechanisms of transmission (Echinococcosis -26.15%, Toxoplasmosis -16.69% and Trichomonosis – 9.57%) are a result of their specific symptomology. Conclusions: Due to the asymptomatic course intestinal parasitic diseases are found predominately via prophylactic screening. In current conditions of increased migration processes this "hidden" morbidity in the adult population continues to represents a significant epidemiological risk.

Verified
Journal Article
Open access
PDF file
ITIliyan Todorov
Iliyan Todorov
MGMargarita Gospodinova
Margarita Gospodinova
Kalina Pavlova StoyanovaKalina Pavlova Stoyanova
Kalina Pavlova Stoyanova
COVID-19, caused by SARS-CoV-2, is a highly contagious disease with variable clinical presentation. Severe forms are more common in patients with pre-existing chronic conditions. The objective of this study is to evaluate the prognostic value of the Charlson Comorbidity Index (CCI) in relation to disease severity and outcome in hospitalized COVID-19 patients with comorbidities. A retrospective analysis was conducted on 558 patients, hospitalized at the Infectious Diseases Clinic of “St. Marina” University Hospital, Varna, Bulgaria, between March 2020 and March 2021. CCI score was calculated to estimate 10-year survival probabilities. Prevalent comorbidities were arterial hypertension (78.55%), type 2 diabetes (16.09%), and ischemic heart disease (5.82%). A higher number of comorbidities was associated with increased rates of bilateral pulmonary consolidation (χ2 = 6.63, p = 0.010), oxygen therapy needs (χ2 = 5.41, p = 0.020), and mortality (χ2 = 7.88, p = 0.005). Patients with higher CCI scores had worse outcomes. A CCI score above 5 was common among non-survivors and those with pulmonary consolidation and respiratory failure. The findings confirm that advanced age and multiple comorbidities are strong predictors of poor COVID-19 prognosis. Early CCI calculation at hospital admission would help identify high-risk patients and support timely, targeted medical interventions.